Leflunomide Exposure and Teriflunomide Concentrations up to the Third Trimester of Pregnancy: A Case Report

Clin Drug Investig. 2022 Sep;42(9):787-789. doi: 10.1007/s40261-022-01185-z. Epub 2022 Jul 27.

Authors

Paul A G De Klaver¹, Carolien M Geesink², Jasper C A Broen², Luc J J Derijks³

Affiliations

¹ Department of Clinical Pharmacy and Pharmacology, Máxima Medical Center, Veldhoven, The Netherlands. p.deklaver@mmc.nl.
² Department of Rheumatology, Máxima Medical Center, Veldhoven, The Netherlands.
³ Department of Clinical Pharmacy and Pharmacology, Máxima Medical Center, Veldhoven, The Netherlands.

PMID: 35896855
DOI: 10.1007/s40261-022-01185-z

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Crotonates* / adverse effects
Female
Humans
Hydroxybutyrates
Leflunomide
Nitriles
Pregnancy
Pregnancy Trimester, Third
Toluidines* / adverse effects

Substances

Crotonates
Hydroxybutyrates
Nitriles
Toluidines
teriflunomide
Leflunomide